These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11422015)

  • 1. Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study.
    Mouly S; Aymard G; Tillement JP; Caulin C; Bergmann JF; Urien S
    Br J Clin Pharmacol; 2001 Jun; 51(6):557-65. PubMed ID: 11422015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss.
    Mouly S; Aymard G; Diquet B; Caulin C; Bergmann JF
    J Acquir Immune Defic Syndr; 2000 Aug; 24(4):344-51. PubMed ID: 11015151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal absorption and permeability in human immunodeficiency virus-infected patients.
    Pernet P; Vittecoq D; Kodjo A; Randrianarisolo MH; Dumitrescu L; Blondon H; Bergmann JF; Giboudeau J; Aussel C
    Scand J Gastroenterol; 1999 Jan; 34(1):29-34. PubMed ID: 10048729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome.
    Trout H; Mentré F; Panhard X; Kodjo A; Escaut L; Pernet P; Gobert JG; Vittecoq D; Knellwolf AL; Caulin C; Bergmann JF
    Antimicrob Agents Chemother; 2004 Feb; 48(2):538-45. PubMed ID: 14742207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
    Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
    Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of indinavir on HIV-related wasting.
    Carbonnel F; Maslo C; Beaugerie L; Carrat F; Wirbel E; Aussel C; Gobert JG; Girard PM; Gendre JP; Cosnes J; Rozenbaum W
    AIDS; 1998 Oct; 12(14):1777-84. PubMed ID: 9792378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micronutrient supplementation in the AIDS diarrhoea-wasting syndrome in Zambia: a randomized controlled trial.
    Kelly P; Musonda R; Kafwembe E; Kaetano L; Keane E; Farthing M
    AIDS; 1999 Mar; 13(4):495-500. PubMed ID: 10197378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonparametric expectation maximization population modeling of ganciclovir.
    Preston SL; Drusano GL
    J Clin Pharmacol; 1996 Apr; 36(4):301-10. PubMed ID: 8728343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of food on the relative bioavailability of oral ganciclovir.
    Lavelle J; Follansbee S; Trapnell CB; Buhles WC; Griffy KG; Jung D; Dorr A; Connor J
    J Clin Pharmacol; 1996 Mar; 36(3):238-41. PubMed ID: 8690817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons.
    Griffy KG
    AIDS; 1996 Dec; 10 Suppl 4():S3-6. PubMed ID: 9110063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
    Caldés A; Colom H; Armendariz Y; Garrido MJ; Troconiz IF; Gil-Vernet S; Lloberas N; Pou L; Peraire C; Grinyó JM
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4816-24. PubMed ID: 19738014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis.
    Snell GI; Kotsimbos TC; Levvey BJ; Skiba M; Rutherford DM; Kong DC; Williams TJ; Krum H
    J Antimicrob Chemother; 2000 Apr; 45(4):511-6. PubMed ID: 10747829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
    Brown F; Banken L; Saywell K; Arum I
    Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-xylose malabsorption: characteristic finding in patients with the AIDS wasting syndrome and chronic diarrhea.
    Ehrenpreis ED; Ganger DR; Kochvar GT; Patterson BK; Craig RM
    J Acquir Immune Defic Syndr (1988); 1992 Oct; 5(10):1047-50. PubMed ID: 1453320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients.
    Jung D; Griffy K; Dorr A; Raschke R; Tarnowski TL; Hulse J; Kates RE
    J Clin Pharmacol; 1998 Nov; 38(11):1057-62. PubMed ID: 9824788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients.
    Anderson RD; Griffy KG; Jung D; Dorr A; Hulse JD; Smith RB
    Clin Ther; 1995; 17(3):425-32. PubMed ID: 7585846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.
    Sam WJ; Tham LS; Holmes MJ; Aw M; Quak SH; Lee KH; Lim SG; Prabhakaran K; Chan SY; Ho PC
    Clin Pharmacokinet; 2006; 45(1):59-75. PubMed ID: 16430311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of ganciclovir intestinal absorption in presence of absorption enhancers.
    Shah P; Jogani V; Mishra P; Mishra AK; Bagchi T; Misra A
    J Pharm Sci; 2007 Oct; 96(10):2710-22. PubMed ID: 17680662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption of zidovudine in patients with diarrhoea.
    Zorza G; Beaugerie L; Taburet AM; Le Quintrec Y; Singlas E
    Eur J Clin Pharmacol; 1993; 44(5):501-3. PubMed ID: 8359192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group.
    Spector SA; Busch DF; Follansbee S; Squires K; Lalezari JP; Jacobson MA; Connor JD; Jung D; Shadman A; Mastre B
    J Infect Dis; 1995 Jun; 171(6):1431-7. PubMed ID: 7769276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.